drugset / Trial / NCT04701476
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Timeline
- Start
- 2021-05-20
- Primary completion
- 2027-03-31
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |
| Subject | TAS-102 | Small molecule | 60 mg | Oral |
| Subject | tirapazamine | Small molecule | — | Other |